T1	Temporal_Concept 2 13	44-year-old
T2	Qualitative_Concept 14 18	male
T3	Disease_or_Syndrome 24 28	ESRD
T4	Qualitative_Concept 40 45	usual
T5	Finding 46 61	state of health
T6	Temporal_Concept 72 75	day
T7	Health_Care_Activity 79 94	hospitalization
T8	Finding 110 122	unresponsive
T9	Finding 127 136	pulseless
T10	Therapeutic_or_Preventive_Procedure 144 158	hemodialysis .
T11	Medical_Device 162 194	automated external defibrillator
T12	Spatial_Concept 199 205	placed
T13	Qualitative_Concept 213 221	received
T14	Qualitative_Concept 222 233	appropriate
T15	Pathologic_Function 234 239	shock
T16	Population_Group 251 260	transient
T17	Enzyme 261 266	CPR .
T18	Functional_Concept 274 281	brought
T19	Health_Care_Related_Organization 289 309	emergency department
T20	Spatial_Concept 314 321	further
T21	Health_Care_Activity 322 334	management .
T22	Functional_Concept 339 346	history
T23	Functional_Concept 347 355	included
T24	Disease_or_Syndrome 395 433	human immunodeficiency virus infection
T25	Disease_or_Syndrome 449 480	secondary hyperparathyroidism .
T26	Finding 501 523	hemodynamically stable
T27	Finding 528 537	euvolemic
T28	Health_Care_Activity 541 547	exam .
T29	Temporal_Concept 548 555	Initial
T30	Idea_or_Concept 556 571	laboratory data
T31	Qualitative_Concept 572 580	revealed
T32	Quantitative_Concept 584 595	uncorrected
T33	Finding 607 611	1.65
T34	Intellectual_Product 632 639	2.12.55
T35	Pharmacologic_Substance 655 670	ionized calcium
T36	Pharmacologic_Substance 663 670	calcium
T37	Finding 674 678	0.71
T38	Pharmacologic_Substance 724 733	potassium
T39	Pharmacologic_Substance 784 793	magnesium
T40	Pharmacologic_Substance 851 861	phosphorus
T41	Quantitative_Concept 865 869	0.97
T42	Quantitative_Concept 883 889	normal
T43	Quantitative_Concept 899 905	mmol/L
T44	Temporal_Concept 914 921	Initial
T45	Intellectual_Product 922 939	electrocardiogram
T46	Animal 940 946	showed
T47	Finding 949 961	sinus rhythm
T48	Finding 969 990	prolonged QT interval
T49	Qualitative_Concept 995 1002	diffuse
T50	Finding 1003 1009	T-wave
T51	Quantitative_Concept 1010 1017	changes
T52	Finding 1071 1090	torsades de pointes
T53	Food 1097 1102	Fig .
T54	Finding 1123 1137	unresponsive .
T55	Finding 1151 1163	resuscitated
T56	Functional_Concept 1168 1179	transferred
T57	Manufactured_Object 1187 1208	intensive care unit .
T58	Health_Care_Activity 1209 1218	Treatment
T59	Disease_or_Syndrome 1226 1255	secondary hyperparathyroidism
T60	Idea_or_Concept 1265 1274	initiated
T61	Quantitative_Concept 1275 1276	3
T62	Temporal_Concept 1277 1282	years
T63	Temporal_Concept 1283 1288	prior
T64	Finding 1369 1375	normal
T65	Quantitative_Concept 1386 1392	pmol/L
T66	Functional_Concept 1403 1411	included
T67	Pharmacologic_Substance 1412 1424	paricalcitol
T68	Therapeutic_or_Preventive_Procedure 1430 1442	hemodialysis
T69	Temporal_Concept 1447 1452	daily
T70	Pharmacologic_Substance 1453 1465	cinacalcet .
T71	Temporal_Concept 1466 1477	Three weeks
T72	Temporal_Concept 1478 1486	prior to
T73	Pharmacologic_Substance 1503 1513	cinacalcet
T74	Clinical_Attribute 1514 1518	dose
T75	Quantitative_Concept 1523 1532	increased
T76	Finding 1538 1540	60
T77	Functional_Concept 1541 1559	to 90 mg daily due
T78	Quantitative_Concept 1544 1546	90
T79	Quantitative_Concept 1547 1591	mg daily due to an iPTH level of 85.6 pmol/L
T80	Temporal_Concept 1550 1555	daily
T81	Laboratory_Procedure 1566 1576	iPTH level
T82	Pharmacologic_Substance 1598 1605	calcium
T83	Quantitative_Concept 1610 1614	2.11
T84	Pharmacologic_Substance 1628 1638	phosphorus
T85	Conceptual_Entity 1669 1673	home
T86	Pharmacologic_Substance 1674 1685	medications
T87	Functional_Concept 1686 1694	included
T88	Pharmacologic_Substance 1717 1727	nifedipine
T89	Pharmacologic_Substance 1737 1759	metoprolol succinate .
T90	Pharmacologic_Substance 1775 1785	cinacalcet
T91	Pharmacologic_Substance 1804 1813	magnesium
T92	Pharmacologic_Substance 1832 1839	calcium
T93	Functional_Concept 1845 1859	administered .
T94	Conceptual_Entity 1869 1876	factors
T95	Qualitative_Concept 1877 1884	capable
T96	Functional_Concept 1888 1896	inducing
T97	Disease_or_Syndrome 1897 1909	hypocalcemia
T98	Qualitative_Concept 1915 1927	identified .
T99	Finding 1932 1941	diagnosis
T100	Finding 1945 1964	torsades de pointes
T101	Qualitative_Concept 1965 1980	associated with
T102	Finding 1981 2002	prolonged QT interval
T103	Quantitative_Concept 2006 2010	part
T104	Functional_Concept 2011 2017	due to
T105	Pharmacologic_Substance 2018 2036	cinacalcet-induced
T106	Qualitative_Concept 2037 2043	severe
T107	Disease_or_Syndrome 2044 2056	hypocalcemia
T108	Functional_Concept 2061 2067	made .
T109	Temporal_Concept 2068 2072	Once
T110	Element__Ion__or_Isotope 2077 2095	total body calcium
T111	Fully_Formed_Anatomical_Structure 2077 2087	total body
T112	Anatomical_Structure 2083 2087	body
T113	Pharmacologic_Substance 2088 2095	calcium
T114	Clinical_Attribute 2115 2126	QT interval
T115	Research_Activity 2127 2137	normalized
T116	Intellectual_Product 2145 2162	electrocardiogram
T117	Spatial_Concept 2170 2177	further
T118	Finding 2178 2190	ar-rhythmias
T119	Functional_Concept 2196 2206	observed .
T120	Pharmacologic_Substance 2207 2224	Phosphate binders
T121	Pharmacologic_Substance 2229 2238	vitamin D
T122	Pharmacologic_Substance 2239 2246	sterols
T123	Occupational_Activity 2267 2277	management
T124	Disease_or_Syndrome 2282 2311	secondary hyperparathyroidism
T125	Patient_or_Disabled_Group 2315 2323	patients
T126	Disease_or_Syndrome 2329 2335	ESRD .
T127	Pharmacologic_Substance 2336 2346	Cinacalcet
T128	Temporal_Concept 2351 2359	recently
T129	Functional_Concept 2360 2370	introduced
T130	Conceptual_Entity 2377 2388	alternative
T131	Occupational_Activity 2398 2405	working
T132	Amino_Acid__Peptide__or_Protein 2414 2438	calcium sensing receptor
T133	Activity 2442 2451	enhancing
T134	Functional_Concept 2456 2470	sensitivity to
T135	Cell_Component 2471 2484	extracellular
T136	Pharmacologic_Substance 2485 2492	calcium
T137	Activity 2505 2515	inhibiting
T138	Functional_Concept 2520 2529	release .
T139	Disease_or_Syndrome 2530 2542	Hypocalcemia
T140	Functional_Concept 2548 2554	common
T141	Phenomenon_or_Process 2597 2606	mitigated
T142	Temporal_Concept 2614 2624	concurrent
T143	Functional_Concept 2625 2631	use of
T144	Pharmacologic_Substance 2632 2645	calcium-based
T145	Pharmacologic_Substance 2632 2655	calcium-based phosphate
T146	Pharmacologic_Substance 2646 2665	phosphate binders .
T147	Medical_Device 2656 2665	binders .
T148	Functional_Concept 2666 2677	Symptomatic
T149	Disease_or_Syndrome 2678 2690	hypocalcemia
T150	Functional_Concept 2691 2698	induced
T151	Pharmacologic_Substance 2702 2712	cinacalcet
T152	Qualitative_Concept 2734 2740	OPTIMA
T153	Quantitative_Concept 2749 2753	only
T154	Patient_or_Disabled_Group 2759 2767	patients
T155	Idea_or_Concept 2768 2777	presented
T156	Laboratory_Procedure 2785 2804	serum calcium level
T157	Quantitative_Concept 2819 2824	mg/dL
T158	Quantitative_Concept 2831 2835	1.87
T159	Manufactured_Object 2887 2891	form
T160	Qualitative_Concept 2924 2928	seen
T161	Patient_or_Disabled_Group 2932 2940	patients
T162	Temporal_Concept 2946 2955	prolonged
T163	Cell 2956 2969	cardiomyocyte
T164	Intellectual_Product 2996 3005	exhibited
T165	Intellectual_Product 3009 3026	electrocardiogram
T166	Finding 3030 3037	long QT
T167	Temporal_Concept 3038 3049	intervals .
T168	Finding 3083 3097	hypomagnesemia
T169	Functional_Concept 3098 3106	increase
T170	Idea_or_Concept 3107 3111	risk
T171	Finding 3115 3134	torsades de pointes
T172	Disease_or_Syndrome 3166 3178	Hypocalcemia
T173	Spatial_Concept 3179 3186	further
T174	Functional_Concept 3187 3196	increases
T175	Idea_or_Concept 3197 3201	risk
T176	Functional_Concept 3218 3229	development
T177	Temporal_Concept 3233 3238	early
T178	Patient_or_Disabled_Group 3265 3273	patients
T179	Finding 3274 3284	arrhythmia
T180	Functional_Concept 3289 3292	not
T181	Conceptual_Entity 3293 3300	resolve
T182	Laboratory_Procedure 3311 3330	serum calcium level
T183	Inorganic_Chemical 3354 3366	electrolytes
T184	Functional_Concept 3372 3382	replaced .
T185	Quantitative_Concept 3414 3417	one
T186	Qualitative_Concept 3425 3430	first
T187	Health_Care_Activity 3431 3439	reported
T188	Clinical_Attribute 3431 3445	reported cases
T189	Functional_Concept 3440 3445	cases
T190	Pharmacologic_Substance 3449 3467	cinacalcet-induced
T191	Disease_or_Syndrome 3468 3480	hypocalcemia
T192	Functional_Concept 3481 3493	resulting in
T193	Finding 3494 3513	torsades de pointes
T194	Disease_or_Syndrome 3518 3534	cardiac arrest .
T195	Idea_or_Concept 3538 3549	recommended
T196	Laboratory_Procedure 3582 3595	serum calcium
T197	Laboratory_Procedure 3600 3622	ionized calcium levels
T198	Diagnostic_Procedure 3633 3641	measured
T199	Temporal_Concept 3651 3655	week
T200	Functional_Concept 3662 3672	initiation
T201	Health_Care_Activity 3676 3691	dose adjustment
T202	Pharmacologic_Substance 3695 3707	cinacalcet .
T203	Temporal_Concept 3708 3712	Once
T204	Quantitative_Concept 3715 3731	maintenance dose
T205	Temporal_Concept 3755 3762	monthly
T206	Health_Care_Activity 3763 3773	monitoring
T207	Laboratory_Procedure 3777 3790	serum calcium
T208	Qualitative_Concept 3814 3824	importance
T209	Functional_Concept 3828 3837	adherence
T210	Spatial_Concept 3841 3845	oral
T211	Therapeutic_or_Preventive_Procedure 3846 3869	calcium supplementation
T212	Temporal_Concept 3870 3879	as needed
T213	Finding 3890 3898	stressed
T214	Patient_or_Disabled_Group 3908 3918	patients .
T215	Congenital_Abnormality 3919 3932	Abnormalities
T216	Laboratory_or_Test_Result 3936 3951	serum potassium
T217	Finding 3982 3985	EKG
T218	Qualitative_Concept 3994 4001	diffuse
T219	Finding 4002 4022	T wave abnormalities
T220	Finding 4027 4053	QT interval prolongation ;
T221	Intellectual_Product 4030 4038	interval
T222	Medical_Device 4056 4071	cardiac monitor
T223	Medical_Device 4072 4078	strips
T224	Patient_or_Disabled_Group 4089 4096	patient
T225	Animal 4097 4104	showing
T226	Disease_or_Syndrome 4105 4140	polymorphic ventricular tachycardia
T227	Idea_or_Concept 4141 4156	consistent with
T228	Finding 4157 4176	torsades de pointes
T229	Idea_or_Concept 4198 4202	risk
T230	Temporal_Concept 4225 4232	monthly
T231	Therapeutic_or_Preventive_Procedure 4233 4259	monitoring of electrolytes
T232	Geographic_Area 4260 4262	to
T233	Food 4263 4269	ensure
T234	Finding 4270 4302	normal serum levels of potassium
T235	Idea_or_Concept 4325 4338	recommended .
T236	Pharmacologic_Substance 4339 4349	Cinacalcet
T237	Finding 4360 4364	used
T238	Patient_or_Disabled_Group 4379 4387	patients
T239	Qualitative_Concept 4393 4398	known
T240	Intellectual_Product 4399 4411	risk factors
T241	Functional_Concept 4438 4445	history
T242	Temporal_Concept 4476 4486	concurrent
T243	Functional_Concept 4487 4493	use of
T244	Quantitative_Concept 4500 4502	QT
T245	Pharmacologic_Substance 4514 4522	agents .
T246	Professional_or_Occupational_Group 4523 4530	Authors
T247	Activity 4531 4543	contribution
T248	Spatial_Concept 4560 4566	access
T249	Medical_Device 4574 4578	data
T250	Conceptual_Entity 4585 4589	role
T251	Occupation_or_Discipline 4593 4600	writing
T252	Intellectual_Product 4605 4617	manuscript .
